Oral Mesalamine for Ulcerative Colitis
An oral formulation of mesalamine (5-aminosalicylic acid, 5-ASA, Asacol - Proctor & Gamble), was recently approved by the US Food and Drug Administration (FDA) for treatment of mildly to moderately active ulcerative colitis; it has not been approved for maintenance of remissions. Olsalazine (Dipentum), a similar drug (Medical Letter, 32:105, 1990), is approved for maintenance of remissions but not for treatment....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Oral Mesalamine for Ulcerative Colitis
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 877
Article Code: 877b
Date: August 21, 1992
Volume: 34
Pages: 80-81
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 877
Article Code: 877b
Date: August 21, 1992
Volume: 34
Pages: 80-81
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)